Tech Company Financing Transactions

Cabaletta Bio Funding Round

Cabaletta Bio, based in Philadelphia, secured $50 million from 5AM Ventures, Adage Capital Management and Boxer Capital.

Transaction Overview

Company Name
Announced On
1/4/2019
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors

5AM Ventures

Adage Capital Management

Boxer Capital

Cormorant Asset Management

Deerfield Capital (Howie Furst)

Redmile Group

Proceeds Purpose
Proceeds from the financing will support establishment of translational research and advanced manufacturing capabilities to complement Cabaletta's relationship with the Center for Cellular Immunotherapies in the Abramson Center at the University of Pennsylvania (Penn).

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2929 Arch St. 600
Philadelphia, PA 19104
USA
Email Address
Overview
Cabaletta Bio (Nasdaq: CABA) is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases.
Profile
Cabaletta Bio LinkedIn Company Profile
Social Media
Cabaletta Bio Company Twitter Account
Company News
Cabaletta Bio News
Facebook
Cabaletta Bio on Facebook
YouTube
Cabaletta Bio on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Steven Nichtberger
  Steven Nichtberger LinkedIn Profile  Steven Nichtberger Twitter Account  Steven Nichtberger News  Steven Nichtberger on Facebook
Chief Financial Officer
Anup Marda
  Anup Marda LinkedIn Profile  Anup Marda Twitter Account  Anup Marda News  Anup Marda on Facebook
Chief Marketing Officer
David Chang
  David Chang LinkedIn Profile  David Chang Twitter Account  David Chang News  David Chang on Facebook
Chief Technical Officer
Gwendolyn Binder
  Gwendolyn Binder LinkedIn Profile  Gwendolyn Binder Twitter Account  Gwendolyn Binder News  Gwendolyn Binder on Facebook
VP - Bus. Development
Arun Das
  Arun Das LinkedIn Profile  Arun Das Twitter Account  Arun Das News  Arun Das on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/4/2019: Tiburio Therapeutics venture capital transaction
Next: 1/4/2019: Ablative Solutions venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to record all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary